Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.26 – $13.29
91% from low
Borrow rate
0.43%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $119.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $500.0K | −$119.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| R&D | $18.7M | $17.0M | $18.3M | $25.6M | $15.6M | $34.3M | $57.3M | $77.1M |
| Operating income | −$27.1M | −$26.4M | −$27.1M | −$37.4M | −$195.0M | −$53.5M | −$83.0M | −$111.6M |
| EBITDA | −$26.6M | −$25.7M | −$27.1M | −$37.4M | −$30.4M | −$51.8M | −$67.8M | −$94.3M |
| Net income | −$27.4M | −$25.9M | −$26.3M | −$37.3M | −$194.9M | −$51.8M | −$72.9M | −$94.3M |
| Net margin | -5472.8% | — | — | — | — | — | — | — |
| EPS (diluted) | -75.73 | -30.71 | -14.06 | -12.20 | -24.58 | -3.55 | -2.42 | -1.68 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-2.14 | $-2.26–$-2.01 | 2 |
| 2027 | $9M | $-1.98 | $-2.57–$-1.39 | 1 |
| 2028 | $63M | $-1.85 | $-2.40–$-1.29 | 1 |
| 2029 | $405M | $2.19 | $1.53–$2.85 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ATXS.
No tracked institution reports a position in ATXS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2021-08-20 | 1-for-6reverse |
| 2018-12-31 | 1-for-10reverse |
| 2005-03-29 | 104-for-100 |
| 2004-03-18 | 103.75-for-100 |
No one on the platform has traded ATXS yet.
| $667M |
| — |
| ERASErasca, Inc. | $18.29 | +14.24% | $5.7B | — |
| IOVAIovance Biotherapeutics, Inc. | $4.21 | -0.94% | $1.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ATXS is basically gone from the tape now after getting absorbed into $BCRX in that Jan 2026 deal. This isn’t a trading setup anymore, it’s just legacy flow getting folded into a larger biotech story. What used to be a standalone HAE pipeline name (STAR programs, early-stage optionality) is now just part of BioCryst’s balance sheet and execution risk. Anyone still talking $ATXS like it’s a live ticker is basically replaying old data.
View on StockTwits ↗$ATXS Brilliant piece that captures ATXS's situation perfectly. So if you want to update your understanding of ATXS or get to know ATXS better, this is essential reading. https://everyticker.com/quote/ATXS/analysis/astria-therapeutics-unlocking-value-through-a-differentiated-dual-asset-pipeline-nasdaq-atxs
View on StockTwits ↗$BCRX $6.74 Holding long position https://stocktwits.com/search/u/G101SPM?symbol=BCRX BRIEF: BioCryst Pharma completes acquisition of Astria Therapeutics ($ATXS) The transaction strengthens its position as a leader in hereditary angioedema and enhances the company's long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with every-three and every-six month dosing, combined with a high level of attack control, positions navenibart to significantly improve the treatment experience for HAE patients. BioCryst also obtains Astria's early-stage program for atopic dermatitis, STAR0310, for which the company plans to pursue strategic alternatives. The acquisition was completed for an implied transaction value of approximately $700 million.
View on StockTwits ↗$ATXS $12.50 bid Holding long position at $7.60 (net cost) https://stocktwits.com/G101SPM/message/602342237 BRIEF: Astria Therapeutics stockholders vote to approve acquisition by BioCryst ($BCRX); parties expect the Merger to close on or about January 23. 2026. note: Carrying long position of BCRX.
View on StockTwits ↗$ATXS / $BCRX – Shareholder Vote $ATXS MergerBrief.com M&A Tracking
View on StockTwits ↗Attached is a compilation of $BCRX & $ATXS operating forecasts as prepared by ATXS management. ATXS management projected BCRX revenues would peak in FY2030. ATXS projects 95% gross margins on Navenibart sales. At the bottom is a comparison of BCRX analyst estimates versus the total revenues forecast by ATXS management. This is for informational purposes only. This is not investment advice. $XBI $IBB $NBI
View on StockTwits ↗@MarkeTimer and $ATXS is down 16% over the last 5 years, we are hoping to merge 2 dumpster fires, that neither c-suite can elevate the share price in the last 5 years, and merge and hope the new company goes up in value? That is some mental gymnastics right there
View on StockTwits ↗$ATXS Equity Corporate Actions Alert #2026 - 13 Information Regarding the Merger of Astria Therapeutics, Inc. (ATXS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-13 At a special meeting to be held on January 21, 2026, the shareholders of Astria Therapeutics, Inc. (ATXS) will vote on the proposed merger with BioCryst Pharmaceuticals, Inc. (BCRX). The merger is tentatively scheduled to close prior to the market open on January 23, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on January 22, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (January 23rd) and will be suspended effective January 26, 2026.
View on StockTwits ↗$ATXS who’s holding for the sale next month? Current stock price is a 2 percent profit for me and I’ve been in since this was catb. It’s very tempting to sell and get out with some profit after all these years of reverse splits, failed studies, and takeovers.
View on StockTwits ↗$ATXS Share Price: $13.10 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.29 – $5.24 Potential Upside: 51% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATXS $APA $GM $AMKR $CX Five different sectors, one story: strength on strength and Who got the real stamina? https://stocksrunner.com/news/2025-12-03-52-week-highs-surge-as-breakout-stocks-hit-fresh-peaks
View on StockTwits ↗$BCRX Receives Early Termination of HSR Waiting Period for $ATXS Acquisition https://www.globenewswire.com/news-release/2025/12/03/3198739/29446/en/BioCryst-Receives-Early-Termination-of-HSR-Waiting-Period-for-Astria-Acquisition.html "Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions."
View on StockTwits ↗There is some resilience here. It just takes a buyout. $ACB $ATXS $MEDXF (Mutiny on the Bounty, Movie 1935)
View on StockTwits ↗RECAP 11/12 Chatter: $NVA + DOD Contract $WULF + Anthropic Expansion RECAP 11/12 +Pos Comments: $NTAP + BWG RECAP 11/12 -Neg Comments: $ATXS - Cantor Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.